36.52
+0.16(+0.44%)
Currency In USD
| Previous Close | 36.36 |
| Open | 36.29 |
| Day High | 36.71 |
| Day Low | 35.51 |
| 52-Week High | 60.37 |
| 52-Week Low | 29.59 |
| Volume | 196,876 |
| Average Volume | 1.06M |
| Market Cap | 3.45B |
| PE | -6.26 |
| EPS | -5.83 |
| Moving Average 50 Days | 36.58 |
| Moving Average 200 Days | 43.55 |
| Change | 0.16 |
If you invested $1000 in Ultragenyx Pharmaceutical Inc. (RARE) 10 years ago, it would be worth $351.63 as of July 01, 2025 at a share price of $36.52. Whereas If you bought $1000 worth of Ultragenyx Pharmaceutical Inc. (RARE) shares 5 years ago, it would be worth $431.42 as of July 01, 2025 at a share price of $36.52.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome
GlobeNewswire Inc.
Jun 27, 2025 12:00 PM GMT
Phase 3 Aspire study enrollment on track to complete in 2025 Aurora study to evaluate GTX-102 in other Angelman syndrome genotypes and ages expected to initiate later this year NOVATO, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceut
Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire Inc.
Jun 03, 2025 9:00 PM GMT
NOVATO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report
GlobeNewswire Inc.
May 14, 2025 8:30 PM GMT
NOVATO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2024 Impact Report today, which covers the company’s approach to corporate responsibility. The report highlights efforts to transform the li